Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Key Inclusion Criteria:

1. Must have completed the Week 12 Visit in MBX-2H1002 Study.

2. Is an adult ≥18 years of age at the time of the Screening visit of this extension study.

3. Has a diagnosis of one of the following types of hypoparathyroidism for at least 26 weeks prior to the

Screening visit:

1. Postsurgical chronic hypoparathyroidism

2. Idiopathic hypoparathyroidism

3. Autoimmune hypoparathyroidism

4. Can comprehend and is willing to sign an informed consent form (ICF), and abide by the study restrictions, study visits, and procedures.

5. In the opinion of the investigator, must be able to successfully demonstrate reconstitution and self-administration of study drug.